Form 4 Tracker
Alexandra Balcom

Chief Financial Officer; Director · 5 filings · Latest: Jun 2, 2026

CRESCENT BIOPHARMA, INC.
Nuvalent, Inc.
TickerOwnerRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Filing
NUVL
Alexandra BalcomJul 1, 2026
Proposed Sale
$123.5322,860$2.8M
NUVL
Alexandra BalcomChief Financial OfficerJun 1, 2026
Sale
$98.6911,430$1.1M85,533
NUVL
Alexandra BalcomChief Financial OfficerJun 1, 2026
Option Exercise
$6.8911,430$78.8K96,963
NUVL
Alexandra BalcomChief Financial OfficerMay 1, 2026
Sale
$99.0011,430$1.1M85,533
NUVL
Alexandra BalcomChief Financial OfficerMay 1, 2026
Option Exercise
$3.2511,430$37.2K96,963
NUVL
Alexandra BalcomChief Financial OfficerApr 1, 2026
Sale
$105.2111,430$1.2M85,533
NUVL
Alexandra BalcomChief Financial OfficerApr 1, 2026
Option Exercise
$1.0811,430$12.3K96,963
NUVL
Alexandra BalcomChief Financial OfficerMar 25, 2026
Sale
$100.1613,700$1.4M85,533
NUVL
Alexandra BalcomChief Financial OfficerMar 24, 2026
Sale
$95.7511,430$1.1M99,233
NUVL
Alexandra BalcomChief Financial OfficerMar 24, 2026
Option Exercise
$1.0811,430$12.3K110,663
NUVL
Alexandra BalcomMar 24, 2026
Proposed Sale
$96.4359,420$5.7M
NUVL
Alexandra BalcomJan 6, 2026
Proposed Sale
$97.587,417$723.8K
NUVL
Alexandra BalcomDec 8, 2025
Proposed Sale
$109.607,084$776.4K
NUVL
Alexandra BalcomNov 17, 2025
Proposed Sale
$93.7213,854$1.3M
NUVL
Alexandra BalcomOct 13, 2025
Proposed Sale
$89.3248,558$4.3M
NUVL
Alexandra BalcomSep 29, 2025
Proposed Sale
$81.3060,000$4.9M
NUVL
Alexandra BalcomJun 27, 2025
Proposed Sale
$80.00129,480$10.4M
NUVL
Alexandra BalcomJan 6, 2025
Proposed Sale
$80.784,250$343.3K
NUVL
Alexandra BalcomSep 30, 2024
Proposed Sale
$102.1230,000$3.1M